FOXM1 Is an Oncogenic Mediator in Ewing Sarcoma

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Christensen, Laura ^a   Joo, Jay ^a   Lee, Sean ^a   Wai, Daniel ^a   Triche, Timothy J ^a   May, William A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; EWING SARCOMA; EWS FLI1 GENE; FOXM1 GENE; FUSION GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; ONCOGENE; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; TUMOR CELL LINE;

ADOLESCENT; ANIMALS; APOPTOSIS; BIOPSY; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SIGNAL TRANSDUCTION; THIOSTREPTON; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872869719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054556     Document Type: Article

References (40)

1. Balamuth NJ, Womer RB, (2010) Ewing's sarcoma. Lancet Oncol 11: 184-192.
2. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, et al. (2004) Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22: 2873-2876.
3. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by translocation in human tumours. Nature 359: 162-165.
4. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, et al. (1993) Ewing sarcoma 11;22 translocation produces a chimeric factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 90: 5752-5756.
5. Lessnick SL, Ladanyi M, (2012) Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 7: 145-159.
6. Myatt SS, Lam EW, (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859.
7. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, et al. (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136.
8. Wierstra I, Alves J, (2007) FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388: 1257-1274.
9. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R, (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6: 744-750.
10. Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, et al. (2010) Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 36: 151-156.
11. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, et al. (2011) FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20: 427-442.
12. Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, et al. (2011) FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 71: 4292-4302.
13. Priller M, Poschl J, Abrao L, von Bueren AO, Cho YJ, et al. (2011) Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17: 6791-6801.
14. Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC, (2011) Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat 126: 803-810.
15. Raychaudhuri P, Park HJ, (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71: 4329-4333.
16. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, et al. (2002) FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773-4780.
17. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, et al. (2008) The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27: 3282-3291.
18. Joo J, Christensen L, Warner K, States L, Kang HG, et al. (2009) GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 4: e7608.
19. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S, (2011) The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 3: 725-731.
20. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, et al. (2006) Dual degradation signals control Gli protein stability and tumor formation. Genes Dev 20: 276-281.
21. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. (1993) The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393-7398.
22. Liu M, Dai B, Kang SH, Ban K, Huang FJ, et al. (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66: 3593-3602.
23. Wonsey DR, Follettie MT, (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65: 5181-5189.
24. Owen LA, Kowalewski AA, Lessnick SL, (2008) EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 3: e1965.
25. Kinsey M, Smith R, Lessnick SL, (2006) NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 4: 851-859.
26. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, et al. (2009) GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 284: 9074-9082.
27. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, et al. (2006) Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 66: 9731-9735.
28. Bhat UG, Halasi M, Gartel AL, (2009) FoxM1 is a general target for proteasome inhibitors. PLoS One 4: e6593.
29. Bhat UG, Halasi M, Gartel AL, (2009) Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 4: e5592.
30. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, et al. (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7: 2022-2032.
31. Gartel AL, (2011) Thiostrepton, proteasome inhibitors and FOXM1. Cell Cycle 10: 4341-4342.
32. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, et al. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326: 572-574.
33. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, et al. (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15: 750-756.
34. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, et al. (2009) FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28: 2908-2918.
35. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, et al. (2011) ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 10: 1046-1058.
36. Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, et al. (2011) Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 6: e23790.
37. Xia LM, Huang WJ, Wang B, Liu M, Zhang Q, et al. (2009) Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem 106: 247-256.
38. Lu G, Punj V, Chaudhary PM, (2008) Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7: 603-608.
39. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, et al. (2008) Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 37-45.
40. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, et al. (2005) A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103: 1431-1438.